NCT02424279

Brief Summary

Pancreatic cancer is a difficult to treat disease, mainly due to the fact that diagnosis is made usually in the late stage of this condition. One of the treatment methods of pain accompanying this neoplasm is thoracoscopic splanchnicectomy. It has been shown that it is a safe procedure with a small percentage of complications, nevertheless it is often use as the last stage in pain management what significantly decreases its effectiveness. The aim of this study is to determinate the effect of invasive pain treatment (splanchnicectomy) in patients with advanced pancreatic cancer on subjective pain perception at rest, in movement and after meals (measured with the BPI, QLQ- C30 and FACIT questionnaires), and suffering (measured with PRISM projection test), the use of painkillers during the disease and patients' overall survival. Moreover the investigators want to check if early performance of splanchnicectomy (on lower steps of analgesic ladder WHO) is combined with better therapeutic effect of this treatment.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for not_applicable pancreatic-cancer

Timeline
Completed

Started Sep 2014

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2014

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

January 2, 2015

Completed
4 months until next milestone

First Posted

Study publicly available on registry

April 23, 2015

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2017

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2017

Completed
Last Updated

April 23, 2015

Status Verified

April 1, 2015

Enrollment Period

2.7 years

First QC Date

January 2, 2015

Last Update Submit

April 18, 2015

Conditions

Keywords

pancreatic cancerpainsplanchnicectomy

Outcome Measures

Primary Outcomes (1)

  • Change from baseline pain intensity at 1 year (BPI questionnaires)

    one year

Secondary Outcomes (1)

  • Quality of life and pain intensity measurement (measured with the QLQ- C30, FACIT and BPI questionnaires)

    From date of randomization until the date of death from any cause,assessed up to 100 months

Study Arms (2)

Surgical treatment

ACTIVE COMPARATOR

Patients from the first group will undergo thoracoscopic splanchnicectomy. The surgery will be performed in general anaesthesia, with tracheal intubation in prone position. The greater splanchnic nerve will be identified at its origin in sympathetic trunk, dissected together with all collaterals all the way down to the diaphragm and excised. Additional splanchnic nerves (smaller, minimus) will be incised or excised if connected to the greater splanchnic nerve. Single sutures will be applied to the skin. Then the procedure will be repeated on the contralateral side.

Procedure: Splanchnicectomy

Conservative Treatment

NO INTERVENTION

Patients from the second group will be offered best available conservative pain treatment. The list of medication on stage 1 will include: paracetamol, ibuprofen, diclofenac. On stage 2: stage 1 + codeine and tramadol. On stage 3: stage 2 + morphine, fentanyl, oxycodone, pethidine. Oral and transcutaneous routes will be preferred to intravenous, intramuscular and subcutaneous. A need for elevation to the next step of analgesic ladder will be considered when the pain will be stronger than 6 points in Numeric Rating Scale (NRS) and will be present for more than 5 days.

Interventions

Surgical treatment

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients diagnosed with pancreatic cancer
  • Age over 18 years
  • Signed informed consent to participate in the study

You may not qualify if:

  • Age under 18 years
  • Intellectual inability to fill the questionnaires
  • Co-occurrence of a disease in which significant chronic pain exists, which was recognized before the onset of pancreatic cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk.

Gdansk, Poland

RECRUITING

Related Publications (1)

  • Dobosz L, Stefaniak T, Dobrzycka M, Wieczorek J, Franczak P, Ptaszynska D, Zasada K, Kanyion P. Invasive treatment of pain associated with pancreatic cancer on different levels of WHO analgesic ladder. BMC Surg. 2016 Apr 18;16:20. doi: 10.1186/s12893-016-0136-3.

MeSH Terms

Conditions

Pancreatic NeoplasmsPain

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Łukasz Dobosz, M.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

January 2, 2015

First Posted

April 23, 2015

Study Start

September 1, 2014

Primary Completion

May 1, 2017

Study Completion

September 1, 2017

Last Updated

April 23, 2015

Record last verified: 2015-04

Locations